Intravenous tirofiban before endovascular thrombectomy — Competitive Intelligence Brief

Intravenous tirofiban before endovascular thrombectomy (Intravenous tirofiban before endovascular thrombectomy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor. Area: Cardiovascular / Neurology.

phase 3 Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa receptor Cardiovascular / Neurology Small molecule

Target snapshot

Intravenous tirofiban before endovascular thrombectomy (Intravenous tirofiban before endovascular thrombectomy) — General Hospital of Shenyang Military Region. Tirofiban is a platelet glycoprotein IIb/IIIa inhibitor that prevents platelet aggregation and thrombus formation during endovascular thrombectomy for acute ischemic stroke.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous tirofiban before endovascular thrombectomy TARGET	Intravenous tirofiban before endovascular thrombectomy	General Hospital of Shenyang Military Region	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Glycoprotein IIb/IIIa inhibitors	Glycoprotein IIb/IIIa inhibitors	University of Luebeck	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
A-Phase: tirofiban; Z-Phase simvastatin	A-Phase: tirofiban; Z-Phase simvastatin	Organon and Co	phase 3	Antiplatelet agent + HMG-CoA reductase inhibitor (combination therapy)	Glycoprotein IIb/IIIa receptor (tirofiban); HMG-CoA reductase (simvastatin)
abciximab intravenously	abciximab intravenously	University of Leipzig	phase 3	GP IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Centocor, Inc. · 1 drug in this class
3. General Hospital of Shenyang Military Region · 1 drug in this class
4. Ministry of Science and Technology of the People´s Republic of China · 1 drug in this class
5. Organon and Co · 1 drug in this class
6. Ottawa Heart Institute Research Corporation · 1 drug in this class
7. University of Leipzig · 1 drug in this class
8. University of Luebeck · 1 drug in this class
9. Università degli Studi di Ferrara · 1 drug in this class